Tesamorelin dosage protocol

What the compound is

Tesamorelin (Egrifta) is a peptide, which is a short chain of amino acids (PMID 41966639). It is a growth hormone-releasing hormone (GHRH) synthetic analog (PMID 39813152, PMID 34665524).

It is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH) (PMID 38905488). The World Anti-Doping Agency (WADA) prohibits the administration of GHRH and its synthetic analogs (PMID 34665524).

How it is thought to work

Tesamorelin, as a growth hormone secretagogue, is thought to activate IGF-1 signaling (PMID 41490200). It is believed to reduce abdominal obesity and increase insulin-like growth factor 1 (IGF-1) (PMID 39813152).

Peptides like tesamorelin exert influence over tissue regeneration, inflammation resolution, and neuromuscular recovery by acting on key pathways such as PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK (PMID 41490200).

What laboratory and animal studies report

Laboratory studies have investigated the in vitro metabolism and detection of tesamorelin in fortified urine, identifying major in vitro metabolites to aid in detecting GHRH administration (PMID 34665524, laboratory).

The limits of detection for target peptides, including tesamorelin, were generally 1 ng/ml or less in laboratory testing (PMID 34665524, laboratory).

Human evidence so far

Tesamorelin is approved for treating HIV-associated lipodystrophy (PMID 41476424, human). A randomized double-blind clinical trial in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease showed that tesamorelin 2 mg once daily significantly declined visceral fat, hepatic fat, and trunk-to-appendicular fat ratio over 12 months compared to placebo (PMID 38905488, human). This trial included 38 participants on integrase inhibitor (INSTI)-based regimens (PMID 38905488, human).

Tesamorelin was well tolerated in this human trial, with a similar frequency of adverse events, including hyperglycemia, between treatment and placebo groups. It had beneficial effects on body composition without exacerbating glycemic control in PWH on INSTI-based regimens (PMID 38905488, human).

A 6-month phase 2 randomized open-label clinical trial involving 73 virally suppressed PWH with abdominal obesity evaluated tesamorelin's effect on neurocognitive impairment (NCI). The tesamorelin group showed a greater reduction in waist circumference (median difference, -2.7 cm; P = 0.015) than the standard of care group, and IGF-1 levels increased (PMID 39813152, human). However, cognitive benefits did not significantly differ between groups, and there was no clear benefit of short-term abdominal obesity reduction on NCI (PMID 39813152, human).

Open questions and limitations

While tesamorelin is approved for HIV-associated lipodystrophy, there is no supporting orthopaedic evidence for its use in musculoskeletal conditions (PMID 41476424, human).

The neurocognitive impairment study recognized limitations such as insufficient power and the absence of a placebo arm (PMID 39813152, human).

Key terms explained

Abdominal obesity (AO) is linked to neurocognitive impairment (NCI) in people with HIV, potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1) (PMID 39813152).

Integrase inhibitors (INSTIs) are a mainstay of HIV antiretroviral therapy, though they can be associated with weight gain and adipose tissue dysfunction (PMID 38905488).